GlassScriptPhysician profile
George L Capo
NPI 1154330843
$9,412.77
in general payments reported to CMS, 2019-2025
37 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $1,546 · 2021: $1,402 · 2022: $1,213 · 2023: $1,232 · 2024: $1,389 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,801.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,206.86 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $1,082.82 | 2019-2022 | |
| Novo Nordisk INC | $1,079.17 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $858.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $840.30 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $725.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Zyla Life Sciences, INC. | $457.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $367.16 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.35 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $280.67 | 2022-2024 | Rexulti |
| Valeritas, INC. | $233.67 | 2019 | |
| Pfizer INC. | $213.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $207.98 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $201.61 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $172.30 | 2019-2025 | Livalo, Seglentis, Zoryve |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Capo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.